Gruber F, Grubisić-Greblo H, Kastelan M, Brajac I, Lenković M, Zamolo G
Department of Dermatology, Clinical Hospital Center, Rijeka, Croatia.
J Chemother. 1998 Dec;10(6):469-73. doi: 10.1179/joc.1998.10.6.469.
This open study was conducted in 72 outpatients with acne vulgaris, to compare the clinical efficacy and tolerability of azithromycin and minocycline. Azithromycin was administered as a single oral dose (500 mg/day) for 4 days in four cycles every 10 days and minocycline was administered 100 mg daily for 6 weeks. Improvement was assessed 6 weeks after initiation of treatment with a four-graded scale. A satisfactory clinical response was observed in 75.8% of the patients treated with azithromycin and in 70.5% of those treated with minocycline. There were no significant differences between these two acne treatments in terms of reduction of the number of lesions (p> 0.05). Both agents were well tolerated and mild side effects were reported in 10.3% of azithromycin and 11.7% of minocycline treated patients. We conclude that azithromycin is at least as clinically effective and well tolerated as minocycline as treatment of facial comedonic and papulopustular acne.
这项开放性研究纳入了72例寻常痤疮门诊患者，旨在比较阿奇霉素和米诺环素的临床疗效及耐受性。阿奇霉素采用单次口服给药（500毫克/天），每10天为一个周期，共4个周期，持续4天；米诺环素每日给药100毫克，持续6周。治疗开始6周后，采用四级评分量表评估病情改善情况。接受阿奇霉素治疗的患者中，75.8%观察到满意的临床反应；接受米诺环素治疗的患者中，这一比例为70.5%。在减少皮损数量方面，这两种痤疮治疗方法之间无显著差异（p>0.05）。两种药物耐受性均良好，接受阿奇霉素治疗的患者中10.3%报告有轻微副作用，接受米诺环素治疗的患者中这一比例为11.7%。我们得出结论，在治疗面部粉刺性和丘疹脓疱性痤疮方面，阿奇霉素在临床疗效和耐受性上至少与米诺环素相当。
